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Abstract
Background: To perform a systematic review and meta-analysis on cytokine levels in patients with fibromyalgia
syndrome (FMS).
Methods: Through December 2010 we systematically reviewed the databases PubMed, MEDLINE, and PsycINFO
and screened the reference lists of 22 review articles for suitable original articles. Original articles investigating
cytokines in patients with FMS were included. Data were extracted by two independent authors. Differences of the
cytokine levels of FMS patients and controls were summarized by standardized mean differences (SMD) using a
random effects model. Study quality was assessed applying methodological scores: modified Center of Evidence
Based Medicine, Newcastle-Ottawa-Scale, and Würzburg Methodological Quality Score.
Results: Twenty-five articles were included investigating 1255 FMS patients and 800 healthy controls. Data of 13/25
studies entered meta-analysis. The overall methodological quality of studies was low. The results of the majority of
studies were not comparable because methods, investigated material, and investigated target cytokines differed.
Systematic review of the selected 25 articles revealed that FMS patients had higher serum levels of interleukin (IL)-1
receptor antagonist, IL-6, and IL-8, and higher plasma levels of IL-8. Meta-analysis of eligible studies showed that
FMS patients had higher plasma IL-6 levels compared to controls (SMD = -0.34 [-0.64, -0.03] 95% CI; p = 0.03). The
majority of investigated cytokines were not different between patients and controls.
Conclusions: The pathophysiological role of cytokines in FMS is still unclear. Studies of higher quality and with
higher numbers of subjects are needed.
Background
Fibromyalgia syndrome (FMS) is a complex of symp-
toms that, according to the criteria of the American
College of Rheumatology (ACR), is associated with
chronic widespread pain and at least eleven positive ten-
der points out of 18 [1]. Additional symptoms like fati-
gue, pain associated sleep disturbance, depression, or
gastrointestinal disorders are frequently reported [2].
The pathophysiology of FMS is incompletely understood
and although the syndrome can be characterized by an
identifiable group of signs and symptoms, there is no
recognized etiologic agent and no consistent anatomical
alteration that would qualify FMS as a disease (e.g. Sted-
man’s online medical dictionary http://www.stedmans.
com).
With an estimated prevalence of 0.5% to 5.8% in the
general population of North America and Europe [3,4],
FMS is a frequent condition and better pathophysiologi-
cal knowledge is warranted to more effectively direct
treatment. Although a large number of studies on the
pathophysiology of FMS have been published, there is
still no overall concept explaining all aspects of FMS.
An imbalance of pro- and anti-inflammatory cytokines
is assumed to play a role in the induction and mainte-
nance of pain [5] and several laboratories have investi-
gated cytokine levels in patients with FMS with diverse
results. In non-systematic reviews the potential patho-
physiological role of cytokines has been discussed with
discrepant results [6,7]. A systematic review with a
quantitative synthesis of the cytokine profiles of FMS
patients compared to controls had not been performed
until now. The aims of this systematic review therefore
were to systematically and quantitatively review data on
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considering and assessing study quality.
Methods
Setting
The literature search was initiated as part of the devel-
opment of an evidence-based interdisciplinary guideline
for the diagnosis and therapy of FMS on behalf of the
Association of the Scientific Medical Societies of Ger-
many (AWMF) coordinated by the German Interdisci-
plinary Association of Pain (DIVS) [8]. The search was
later expanded and extended (see below).
Searches
A literature search for original research articles on the
pathophysiology of FMS was performed through Decem-
ber 2010 and the following databases were screened:
PubMed, MEDLINE, and PsycINFO. The keywords (all
languages) “fibromyalgia”, “fibromyalgia syndrome”,
“chronic widespread pain” were used in combination
with “cytokine”, with “cytokine” AND “pathophysiology”,
and also with “review”. Additionally, the reference sec-
tions of 22 review articles that were found using this
search strategy were screened for possibly suitable origi-
nal articles.
Inclusion and exclusion criteria
We only included original full text articles investigating
the pathophysiological role of cytokines in FMS and
excluded the following articles that appeared upon the
search strategy detailed above: double hits, reviews, let-
ters to the editor, papers investigating other disorders,
articles in Danish, all articles that did not investigate
cytokines. First, the titles and abstracts of all articles
found were screened for suitability; the initially chosen
articles were then screened again checking the entire
article.
Data extraction
Two authors independently screened the titles and
abstracts of potentially eligible articles that were
detected by the search strategy described above. The full
text of the selected studies was examined. For data
extraction two authors (NÜ, CS) independently used
standard extraction forms. All authors cross-checked the
extraction forms for correctness. Data were categorized
for the material investigated. Blood measurements were
performed in serum, plasma, and whole blood; accord-
ingly these data were first assessed separately and then
all study results on “blood” were compared.
Quality assessment
For evaluating the quality of the selected studies we
applied two validated scales: the Level of Evidence of
the Oxford Center for Evidence-based Medicine (CEBM,
http://www.cebm.net/index.aspx?o=1025) and the New-
castle-Ottawa Quality Assessment Scale (NOS) http://
www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
We modified the CEBM to make it applicable for
scientific papers investigating pathophysiological aspects
with bench research (Table 1). Additionally, we aimed at
evaluating the quality of the laboratory methods used.
To our knowledge there is no standardized rating scale
to assess the quality of laboratory methods in scientific
papers. Therefore we created the Würzburg Methodolo-
gical Quality Score (W-MeQS, Table 2). W-MeQS con-
sists of twelve items that are relevant for high quality of
a laboratory method. For each item fulfilled one point is
given; the score is the sum of all points achieved divided
by the number of items that were applicable. If the tar-
get of interest was measured by just one method this
score marks the end score. If more than one method
was used, a subscore is calculated for each method as
described and the end-score is calculated as mean of the
subscores. The scores were evaluated as follows: ≤ 0.4:
low quality; > 0.4 medium quality; ≥ 0.8 high quality.
Data synthesis and analysis
Meta-analysis was performed using RevMan analysis
software (RevMan 5.1.2) of the Cochrane Collaboration
[9]. Standardized mean differences (SMD) were calcu-
lated by means and standard deviations for each
cytokine.
Results
Study selection
For the number of found, selected, excluded and finally
included articles see the algorithm shown in Figure 1.
The initial literature search retrieved the following
numbers of articles: PubMed: 281; MEDLINE: 69; Psy-
cINFO: 2. After exclusion of double hits 115 articles
were chosen and the titles and abstracts were screened
for suitability. The following 90 articles were excluded:
reviews (n = 42), papers investigating other disorders (n
= 26), papers not investigating cytokines (n = 11), letters
to the editor (n = 4), double publications (n = 3), treat-
ment studies (n = 3), and one article in Danish. The
screening of the reference sections of 22 review articles
did not provide further original articles. Finally, 25 arti-
cles were selected for our systematic review [10-34]. A
total of 1255 patients with FMS, 180 patients in disease
control groups, and 800 healthy controls were
investigated.
Of these 25 articles, two articles were not suitable for
meta-analysis because no healthy control group was
investigated [11,26]; seven articles could not be
included, because mean and standard deviations were
not given in the article or could not be calculated (e.g.
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Level Differential diagnosis/symptom prevalence study Blinded Controls Remark/example
1a Systematic review of prospective cohort studies NR NR No systematic reviews available
1b Prospective cohort study with good follow-up NR Implicit An item is assessed (e.g. breast implant) and the
occurrence of FMS is followed prospectively
1c All or none case series Test and
assessment of
results
Obligatory All patients with low IL-4 have FMS, none has
high IL-4
1d 1c Test or
assessment of
results
Obligatory 1c
2a Systematic review (with homogeneity) of NR NR No systematic reviews available
2b and better studies
2b Retrospective cohort study, or poor follow-up NR Implicit FMS patients are investigated now, if they have
had breast implants in the past; large size studies
2c Ecological studies Test and
assessment of
results
Implicit FMS patients are investigated simultaneously, if
they have FMS and if they have low IL-4 levels.
2d 2c Test or
assessment of
results
Implicit 2c
3a Systematic review (with homogeneity) of 3b and
better studies
No systematic reviews available
3b Non-consecutive cohort study, or very limited
population
Test and
assessment of
results
Obligatory FMS patients and controls (limited population)
are now investigated if they have low IL-4
levels
3c 3b Test or
assessment of
results
Obligatory 3b
3d 1c, 2c, 3b Not blinded Obligatory
4 Case series or superseded reference standards All studies
without control
group
Case series with historical controls; case reports
5 Expert opinion without explicit critical appraisal, or
based on physiology, bench research or “first
principles”
NR
Abbreviations: CEMB: Oxford Center for Evidence-based Medicine FMS: fibromyalgia syndrome; NR: not relevant
Table 2 Würzburg Methodological Quality Score (W-MeQS) for the assessment of the quality of laboratory methods.
Item
1 Standardized method OR citation OR new method with adequate description including 2-5?
2 Adequate description of the method itself?
3 Sensitivity limits of the method declared?
4 Adequate internal controls measured?
5 Adequate negative controls measured?
6 Adequate number of samples investigated?
7 Adequate comparison with the control group?
8 All reagent information given?
9 Time points of tissue/blood collection standardized and given?
10 Measurements or data assessment performed in a blinded manner?
11 Adequate data assessment and illustration?
12 Target of interest investigated with > 1 method?
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Page 3 of 15from the standard error of the mean) and were not pro-
vided upon request [10,13,15,20,21,25,27]. Finally, 16
articles were principally suitable for meta-analysis
[12,14,16-19,22-24,28-34]. These articles were then
screened for suitability to be categorized in groups of
articles having investigated the same cytokine with the
same method in the same material; three of the 16 arti-
cles could not be categorized in one of the subgroups
(see below) and therefore could not enter meta-analysis
[12,18,33]. Thus, 13 articles were finally included in the
meta-analysis. Table 3 summarizes key information of
the 25 selected articles and gives the quality scores of
the studies.
Majority of studies with low quality
Only three of the 25 studies (12%) had a modified
CEBM level of 3c [14,15,19]. Twenty-one of the 25
(84%) studies had a modified CEBM level of 3d
[10-13,16-18,20-25,27-34], and one case report of 4 (4%)
[26]. The highest NOS score reached was 4 out of 8;
this was achieved by 5/25 studies (25%) [12,28,30,32].
Eleven out of 25 studies (44%) reached a NOS score of
3 [11,13-17,20,24,25,31,33]; 8/25 studies (32%) had a
NOS score of 2 [10,18,21-23,27,29,34]; one study had a
NOS score of 1 (4%) [26].
In the W-MeQS only 4/25 studies (16%) were of high
methodological quality (score ≥ 0.8) [14,15,29,30]; 7/25
studies (28%) were of medium quality (score > 0.4)
[10,19-21,27,31,33], and 14/25 studies (56%) were of low
quality (score ≤ 0.4) [11-13,16-18,22-26,28,32]. Only 2/
25 studies (8%) had a high NOS and W-MeQS score
[14,15].
These results show that the majority of the studies
were of low methodological quality.
High variability of materials and methods
In twelve studies serum [11,13,19,20,23,25,26,
28,30-32,34], in seven studies peripheral blood mono-
nuclear cells (PBMC) [10,12,18,21,22,24,31], in six stu-
dies plasma [13,14,16,17,29,33], in two studies skin
biopsies [15,27], and in one study whole blood [30] was
investigated. Cytokine levels were investigated with
ELISA in twelve studies [11-14,19,23-25,28,30,31,34],
with bead-based immunoassays in five studies
Literature search through December 2010 
PubMed, Medline (Ovid), PsycINFO (Ovid) 
Fibromyalgia AND cytokine 
Fibromyalgia syndrome AND cytokine 
Chronic widespread pain AND cytokine 
Additionally each line in combination with “AND pathophysiology” 
Additionally each line in combination with “AND review” 
PubMed:  
N = 281 
MEDLINE:  
N = 69 
PsycINFO:  
N = 2 
Original articles: 
All together: 
N = 352 
Among these n = 237 duplicates 
 
N = 115 possibly suitable 
articles 
N = 22 suitable reviews 
Reviews: 
PubMed:  
N = 135 
MEDLINE:  
N = 50 
PsycINFO:  
N = 0 
All together: 
N = 185 
Among these n = 139 duplicates 
 
N = 46 possibly suitable 
reviews 
N = 25 included 
N = 90 excluded 
Reasons for exclusion of original articles: 
N = 42:  reviews 
N = 26:   other disorders investigated  
N = 11:   no cytokines measured 
N = 4:  letters to the editor 
N= 3:   double publication 
N = 3:   treatment studies 
N = 1:   article in Danish 
included = 25 
N = 25 excluded 
N = 0 additionally included articles 
Reasons for exclusion of reviews: 
N = 1: double publication 
N = 16: other disease than FMS or 
CWP 
N = 3: cytokines/chemokines only 
N = 4: other mechanism investigated 
N = 1: article in Japanese 
suitable for metaanalysis = 13 
Figure 1 Algorithm of study selection. The Figure displays the details of the study search and selection process.
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Page 4 of 15Table 3 Characteristics of all studies included in the systematic review investigating cytokines in FMS patients.
Author, yr.
Diagnosis
criteria
N patients/controls a) Material
b) Methods
c) Investigated targets
Results Modified
CEBM
level
NOS W-
MeQS
Hader, 1991
Smythe
12/10 a) CD4+ T-lymphocytes from PBMC
b) T-cell culture; stimulation
experiments with mitogens and
measurement of IL-2 secretion
c) IL-2
FMS: higher concentration of mitogen
was necessary to achieve optimal IL-2
secretion; peak time of IL-2 secretion
was delayed.
Addition of calcium did not correct
the reduction in IL-2 secretion in
patients with FMS; addition of
phorbole myristate acetate led to
normal IL-2 secretion.
3d 2 0.4
Barth, 1999
Wolfe, 1985
12 FMS/6 rheumatoid
arthritis or osteoarthritis
controls/6 controls
a) supernatant of PBMC
b) self established double sandwich
ELISA;
c) IL-4; IL-2; INFg; GM-CSF; IL-5, IL-10
In vitro stimulation of PBMC with
different L-tryptophan preparations: 6/
12 FMS patients, 2/12 controls: IL-5
and IL-10 production
3d 4 0.1
Maes, 1999
ACR
21/33 a) serum
B) ELISA
c) IL-6, sIL-6 R, sIL-1R, IL-1RA
In FMS compared to controls:
IL-6↔
sIL-6R ⇑
sIL-1R ⇑
IL-1RA ⇑
3d 2 0.3
Pay. 2000
ACR
25 FMS/25 chronic
musculoskeletal complaints/
25 controls
a) serum
b) ELISA
c) IL-1b, TNF, IL-6
No difference for pro-inflammatory
cytokines in FMS and controls.
3d 3 0.4
Wallace,
2001
ACR
56/56
Serum, PBMC
a) serum, PBMC, plasma
b) ELISA
c) IL-1b, IL-2, IL-6, IL-8, IL-10, sIL-2R, IL-
1RA, IFNg, TNF
In FMS compared to controls:
IL-1b, IL-2, IL-6, IL-8, IL-10, sIL-2R, IFNg,
TNF: ↔ in sera +PBMC
IL-1RA: ⇑ in serum
IL-8: ⇑ in plasma IL-1 RA, IL-6: ⇑ in
PBMC
IL-6: ⇑ in PBMC of patients with
disease duration > 2 years.
3d 3 0.5
Gür, 2002
ACR
81/32 a) serum
b) ELISA
c) IL-1, IL-2R, IL-6, IL-8
In FMS compared to controls:
IL-1 ↔
IL-2 R ⇑
IL-6 ↔
IL-8 ⇑
3d 2 0.4
Schwarz,
2002
ACR
17/17 a) serum
b) ELISA
c) IL-6
IL-6 ⇑ during tryptophan depletion in
FMS
3d 4 0.3
Amel
Kashipaz,
2003
ACR
22 FMS/CFS/19 a) PBMC
b) intracellular cytokine stain; flow
cytometry
c) IL-1a, IL-6, IL-10, TNF
In FMS compared to controls:
IL-1a ↔
IL-6 ↔
IL-10 ↔
TNF ↔
3d 2 0.7
Salemi,
2003
ACR
53/10 a) skin biopsy
b) RT-PCR, IHC
c) IL-1b, IL-6, TNF
Detectable cytokines in FMS:
IL-1b (19/50)
IL-6 (14/51)
TNF (17/53)
None of the cytokines could be
detected in control skin.
3d 2 0.7
Ardic, 2006
ACR
21/10 a) serum
b) ELISA
c) IL-1 (after balneo therapy)
After balneo therapy:
IL-1↓ in FMS
3d 3 0.2
Üçeyler,
2006
ACR
26/40 a) serum; whole blood
b) qRT-PCR;
ELISA
c) IL-2, IL-4, IL-8, IL-10, TNF, TGF-b1
In FMS compared to controls:
IL-2 ↔
IL-4 ⇓
IL-8 ↔
IL-10 ⇓
TGF-b1 ↔
TNF ↔
3d 4 0.8
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(Continued)
Bazzichi,
2007
ACR
285/40 (16 rheumatoid
arthritis cases, two Sjögren’s
syndrome cases, 16
systemic lupus
erythematosus cases,
four systemic sclerosis cases,
two undifferentiated
connective-
tissue disease cases)/100
a) serum, plasma
b) ELISA
c) IL-1, IL-6, IL-8, IL-10, TNFa
No intergroup difference for cytokines. 3d 3 0.2
Bazzichi,
2007
ACR
80/45 a) plasma
b) ELISA
c) IL-1, IL-6, IL-8, IL-10, TNF
IL-10, IL-8, TNF: FMS > controls 3c 3 0.9
Macedo,
2007
ACR
18/22 a) PBMC
b) automated biochip array; before
and after 1.5 mg of dexamethasone
per os
c) IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-
10, IFNg, TNF
After dexamethasone: reduction of
cytokines FMS > controls.
3d 2 0.4
Kaufmann,
2007
ACR
22/15 CRPS/37 a) T-cells
b) FACS analysis
c) IL-2, IFNg, IL-4, IL-10
No difference in percentage of
cytokine producing cells between
FMS and controls.
3d 2 0.6
Togo,
2008
ACR
7/9 a) plasma
b) Beadlyte multi-cytokine assay
c) IL-10, IL-6, IL-8, IL-1, TNF
No difference between groups.
“FM patients showed a shift to
increased IL-10 in the
nighttime compared to controls.”
3d 2 0.8
Wang, 2008
ACR
20/80 a) serum
b) Bio-Plex cytokine assay
c) IL-6, IL-8, IL-10, IL-4, TNF
At baseline: IL-8 in FMS > controls; no
difference for other cytokines.
3d 4 0.4
Zhang,
2008
ACR
92/69 family members/62
anonymous blood samples
from blood bank
a) plasma
b) Cytokine Twenty-Five-Plex
Antibody Bead Kit
c) MCP-1, Eotaxin, IP-10, IL-13, IL-5, IL-
10, IL-1b, IL-2, IL-4, IL-6, IL-7, IL-8, IL-
12, IL-15, IL-17, TNF, IFNa, IFNg, GM-
CSF, MIG, MIP-1a, MIP-1b, IL-1ra, IL-2r
Eotaxin and MIP: FMS > controls 3d 3 0.5
Feng, 2009
ACR
100 FMS patients and family
members/35 unaffected
parents
a) plasma
b) Cytokine Twenty-Five-Plex
Antibody Bead Kit
c) Eotaxin, MIP.1a, MCP-1, IP10, IL-12,
IL-1b
Rare missense variants of the MEFV
gene are associated with risk of FMS
and are present in a subset of 15% of
FMS patients. This subset had, on
average, high levels of plasma IL-1b
compared to FMS patients without
rare variants, unaffected family
members with or without rare
variants, and unrelated controls of
unknown genotype.
3d 3 0.4
Blanco,
2010
ACR
63/49 a) skin
b) immuno-histochemistry
c) MCP-1, TNF
MCP-1: FMS < controls 3c 3 0.8
Blanco,
2010
ACR
79/59 a) plasma
b) sandwich enzyme immunoassay
kits
c) IL-8, TNF, sTNF-RI, sTNF-RII, MCP-1
Patients with FMS have lower
systemic levels of MCP-2 than
controls.
3d 3 0.4
Hernandez,
2010
ACR
64/25 a) serum
b) ELISA
c) TNF, IL-1, IL-6
TNF: FMS < controls
IL-1: not detectable in FMS
IL-6: FMS > controls
3c 4 0.6
Iannucelli,
2010
ACR
51/25 tension type
headache/15
a) serum
b) multiplex bead-based sandwich
immunoassay
c) IL-1b, IL-1Ra, IL-4, IL-6, IL-8, IL-10,
INFg, TNF
FMS > controls: IL-1RA, IL-6, IL-10, TNF 3d 3 0.7
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Page 6 of 15[17,20,26,29,33], with FACS analysis in two studies
[10,21], with quantitative real-time PCR in one study
[30], with reverse transcription PCR in one study [27],
with immunohistochemistry in one study [15].
There is little overlap in materials and methods used
between different studies investigating cytokine levels in
FMS patients.
Systematic review
Serum (Table 4)
Serum samples of 643 FMS patients, 109 patients in dis-
ease control groups, and 301 healthy controls were
investigated. Only one study reached a modified CEMB
level of 3c [19]; ten studies had a modified CEMB level
of 3d [11,13,20,23,25,28,30-32,34]; one study had a mod-
ified CEMB level of 4 [26]. Four studies had a NOS
score of 4 [19,28,30,32], five studies had a NOS score of
3 [11,13,20,25,31], two studies had a NOS score of 2
[23,34], and one study of 1 [26]. Applying W-MeQS
only one study was of high methodological quality [30];
three studies were of medium quality [19,20,31], and
eight studies of low methodological quality
[11,13,23,25,26,28,32,34].
The following results were reproduced (regardless of
the method used and with a minimum of two indepen-
dent studies): patients with FMS have higher serum
levels of IL-1RA [20,23,31], IL-6 [19,20,28], and IL-8
[32,34]. No intergroup difference was found for serum
IL-6 [13,23,25,31,32,34], IL-1b/IL-1 [13,20,25,31,34],
TNF [13,25,30-32], IL-2 [30,31], IL-10 [13,31,32], IFN-g
[20,31], IL-4 [20,32].
Discrepant results are described for IL-6: IL-6 levels
were found higher in FMS patients compared to con-
trols in three studies [19,20,28]; 2/3 studies were of
medium methodological quality [19,20], 2/3 studies had
a NOS score of 4 [19,28], and 1/3 study had a modified
CEBM of 3c [19]. In six studies no intergroup difference
could be found for serum IL-6 levels [13,23,25,31,32,34];
5/6 studies were of low methodological quality
[13,23,25,32,34], only 1/6 studies reached a NOS score
of 4 [32], and 6/6 studies had a modified CEBM level of
3d [13,23,25,31,32,34]. The better quality of studies
showing elevated serum IL-6 levels in FMS patients
compared to controls favors this finding, although in
more studies (with less quality) no intergroup difference
could be found.
The majority of studies were of low methodological
quality and there was hardly an overlap in the methods
used and the cytokines investigated. Only IL-1RA, IL-6,
and IL-8 were higher expressed in sera of FMS patients,
while for all other cytokines no intergroup difference
could be found.
Plasma (Table 5)
Plasma cytokine levels were investigated in seven studies
[13,14,16,17,29,31,33].
Plasma samples of 699 FMS patients, 109 patients in
disease control groups, and 357 healthy controls were
investigated. Only one study reached a modified CEMB
level of 3c [14]; six studies had a modified CEMB level
of 3d [13,16,17,29,31,33]. Six studies had a NOS score of
3 [13,14,16,17,31,33], one study of 2 [29]. Applying W-
MeQS only two studies were of high methodological
quality [14,29], two studies were of medium [31,33], and
two studies of low methodological quality [16,17].
The following results were reproduced (regardless of
the method used and with a minimum of two indepen-
dent studies): patients with FMS have higher plasma
levels of IL-8 [14,31]. No intergroup difference was
found for plasma IL-1b/IL-1 [13,14,17,29,31,33], IL-6
[13,14,29,31,33], IL-8 [13,16,29,33], TNF
[13,16,29,31,33], and IL-10 [13,29,31,33], MCP-1 and
IP10 [17,33], IL-2 and IFN-g [31,33].
Discrepant results are described for IL-8: IL-8 levels
were found higher in FMS patients compared to con-
t r o l si nt w os t u d i e s[ 1 4 , 3 1 ] ;1 / 2s t u d i e sw a so fm e d i u m
[31] and 1/2 studies was of high methodological quality
[14], both studies had a NOS score of 3, and one study
reached a modified CEBM level of 3c [14]. In four
Table 3 Characteristics of all studies included in the systematic review investigating cytokines in FMS patients.
(Continued)
Ortega,
2010
ACR
9/9 a) PBMC
b) ELISA
c) IL-1b, TNF, IL-6, IL-10
For all cytokines investigated: higher
values at baseline in FMS compared
to controls; after aquatic exercise
levels as in controls.
3d 3 0.3
Ross, 2010
ACR
24/none a) serum
b) bead-based immunofluorescence
assay
c) IL-1a, IL-1b, IL-1RA, IL-6, IL-8, IL-10,
TNF
IL-6 and IL-8: FMS responders (i.e. GH
response to exercise of ≥ 5 ng/mL)
higher than FMS non-responders. For
IL-1a vice versa.
4 1 0.2
Abbreviations:
ACR: American College of Rheumatology; CEMB: Center of Evidence Based Medicine; ELISA: enzyme linked immunosorbent assay; FMS: fibromyalgia syndrome; IL:
interleukin; NOS: Newcastle Ottawa Scale; NR: not reported; PBMC: peripheral blood mononuclear cells; qRT-PCR: quantitative real-time PCR; R: receptor; RA:
receptor antagonist; W-MeQS: Würzburg Methodological Quality Score; yrs: years
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Author, yr.
Diagnosis
criteria
N patients/controls a) Material
b) Methods
c) Investigated
targets
Results Modified
CEBM
level
NOS W-
MeQS
Maes, 1999
ACR
21/33 a) serum
B) ELISA
c) IL-6, sIL-6 R, sIL-1R,
IL-1 RA
In FMS compared to controls:
IL-6↔
sIL-6 R ⇑
sIL-1R ⇑
IL-1 RA ⇑
3d 2 0.3
Pay. 2000
ACR
25 FMS/25 chronic
musculoskeletal
complaints/25 controls
a) serum
b) ELISA
c) IL-1b, TNF, IL-6
No difference for pro-inflammatory cytokines in FMS
and controls.
3d 3 0.4
Wallace,
2001
ACR
56/56 a) serum, PBMC,
plasma
b) ELISA
c) IL-1b, IL-2, IL-6, IL-8,
IL-10, sIL-2 R, IL-1 RA,
IFNg, TNF
In FMS compared to controls:
IL-1b, IL-2, IL-6, IL-8, IL-10, sIL-2 R, IFNg, TNF: ↔ in sera
+PBMC
IL-1 RA: ⇑ in serum
IL-8: ⇑ in plasma
IL-1 RA, IL-6: ⇑ in PBMC
IL-6: ⇑ in PBMC of patients with disease duration > 2
years.
3d 3 0.5
Gür,
2002
ACR
81/32 a) serum
b) ELISA
c) IL-1, IL-2R, IL-6,
IL-8
In FMS compared to controls:
IL-1 ↔
IL-2 R ⇑
IL-6 ↔
IL-8 ⇑
3d 2 0.4
Schwarz,
2002
ACR
17/17 a) serum
b) ELISA
c) IL-6
IL-6 ⇑ during tryptophan depletion in FMS 3d 4 0.3
Ardic, 2006
ACR
21/10 (data not given) a) serum
b) ELISA
c) IL-1 (after balneo
therapy)
After balneo therapy:
IL-1↓ in FMS
3d 3 0.2
Üçeyler,
2006
ACR
26/40 a) serum; whole blood
b) qRT-PCR;
ELISA
c) IL-2, IL-4, IL-8, IL-10,
TNF, TGF b1
In FMS compared to controls:
IL-2 ↔
IL-4 ⇓
IL-8 ↔
IL-10 ⇓
TGF b1 ↔
TNF ↔
3d 4 0.8
Bazzichi,
2007
ACR
285/40 (16 rheumatoid
arthritis cases, two
Sjögren’s
syndrome cases, 16
systemic lupus
erythematosus cases,
four systemic sclerosis
cases, two undifferentiated
connective-
tissue disease cases)/100
a) serum, plasma
b) ELISA
c) IL-1, IL-6, IL-8, IL-10,
TNF
No intergroup difference for cytokines. 3d 3 0.2
Wang, 2008
ACR
20/80 a) serum
b) Bio-Plex cytokine
assay
c) IL-6, IL-8, IL-10, IL-4,
TNF
At baseline: IL-8 in FMS > controls; no difference for
other cytokines.
3d 4 0.4
Hernandez,
2010
ACR
64/25 a) serum
b) ELISA
c) TNF, IL-1, IL-6
TNF: FMS < controls
IL-1: not detectable in FMS
IL-6: FMS > controls
3c 4 0.6
Iannucelli,
2010
ACR
51/25 tension type
headache/15
a) serum
b) multiplex bead-
based sandwich
immunoassay
c) IL-1b, IL-1Ra, IL-4, IL-
6, IL-8, IL-10, INFg, TNF
FMS > controls: IL-1Ra, IL-6, IL-10, TNF 3d 3 0.7
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Page 8 of 15studies no intergroup difference could be found for
plasma IL-8 levels [13,16,29,33]; 2/4 studies were of low
methodological quality [13,16] and 3/4 studies had a
NOS score of 3 [13,16,33]; the only study with high
methodological quality had a NOS score of only 2 [29];
all four studies had a modified CEBM level of 3d. The
better quality of studies showing elevated plasma IL-8
levels in FMS patients compared to controls favors this
finding, although in more studies (with less quality) no
intergroup difference could be found.
The majority of studies were of low methodological
quality with only little overlap in methodology and cyto-
kines investigated. A difference between FMS patients
and controls was found only for IL-8 plasma levels.
When taking studies investigating serum and plasma
together we found no intergroup difference.
Whole blood (Table 6)
Cytokine expression in whole blood of patients with
FMS was investigated in one study including 26 FMS
patients and 40 healthy controls [30]. The study had a
modified CEMB level of 3d, a NOS of 4 and was of high
methodological quality and found reduced levels of the
anti-inflammatory cytokines IL-4 and IL-10 gene expres-
sion in FMS patients compared to controls. These
results were not reproduced.
Peripheral blood mononuclear cells (Table 7)
Cytokine expression in peripheral blood mononuclear
cells (PBMC) was investigated in seven studies
[10,12,18,21,22,24,31].
PBMC of 151 FMS patients, 21 patients in disease
control groups, and 159 healthy controls were investi-
gated. All seven studies had a modified CEMB level of
3d [10,12,18,21,22,24,31]. One study reached a NOS
score of 4 [12], two studies of 3 [24,31], and four studies
of 2 [10,18,21,22]. Applying W-MeQS three studies were
of medium methodological quality [10,21,31] and four
were of low quality [12,18,22,24].
The following results were reproduced (regardless of
the method used and with a minimum of two indepen-
dent studies): no intergroup difference was found for
IL-10 secretion from PBMC between FMS patients and
controls [10,22,31].
FMS patients do not differ in PBMC cytokine levels
from healthy controls.
Skin (Table 8)
Cytokine expression in skin of FMS patients was investi-
gated in two studies including 116 FMS patients, and 59
healthy controls [15,27]. One study had a modified
CEMB level of 3c [15] and one of 3d [27]; one study
had a NOS score of 3 [16], the other of 2 [27]. Applying
W-MeQS one study was of high methodological quality
[16], one study of medium quality [27]. In the study by
Salemi et al. [27] IL-1b, IL-6, and TNF were detectable
in skin samples of a subgroup of FMS patients using
reverse transcription PCR and immunohistochemistry,
while in controls none of these cytokines could be
detected. Blanco et al. [15] investigated TNF and MCP-
1 in skin biopsies using immunohistochemistry and
found lower MCP-1 expression in FMS patients than in
controls. None of the results were reproduced.
Meta-analysis
In the selected 16 papers for meta-analysis authors
investigated different cytokines with various methods.
We therefore created subgroups of papers that investi-
gated the same cytokine with the same or a comparable
Table 4 Characteristics of studies investigating serum levels of cytokines in FMS patients. (Continued)
Ross, 2010
ACR
24/none a) serum
b) bead-based
immunofluorescence
assay
c) IL-1a, IL-1b, IL-1RA,
IL-6, IL-8, IL-10, TNF
IL-6 and IL-8: FMS responders (i.e. GH response to
exercise of ≥ 5 ng/mL) higher than FMS non-
responders. For IL-1a vice versa.
4 1 0.2
FMS > controls
IL-1 RA: Iannuccelli 2010; Maes, 1999; Wallace 2001
IL-6: Iannucelli, 2010; Schwarz, 2002; Hernandez, 2010
IL-8: Gür, 2002; Wang, 2008
FMS = controls
IL-6: Maes, 1999; Pay, 2000; Wallace, 2001; Gür, 2002b; Bazzichi, 2007; Wang 2008
IL-1b/IL-1: Pay, 2000; Wallace, 2001; Gür, 2002b; Bazzichi, 2007; Iannucelli, 2010
TNF: Pay, 2000; Wallace, 2001; Bazzichi, 2007; Wang, 2008
IL-2: Wallace, 2001; Üçeyler, 2006
IL-10: Wallace, 2001; Bazzichi, 2007; Wang, 2008
IFN-g: Wallace, 2001; Iannucelli, 2010
IL-4: Wang, 2008; Iannucelli, 2010
Abbreviations:
ACR: American College of Rheumatology; CEMB: Center of Evidence Based Medicine; ELISA: enzyme linked immunosorbent assay; FMS: fibromyalgia syndrome; IL:
interleukin; KYN: kynurenine; NOS: Newcastle Ottawa Scale; NR: not reported; PBMC: peripheral blood mononuclear cells; qRT-PCR: quantitative real-time PCR; R:
receptor; RA: receptor antagonist; W-MeQS: Würzburg Methodological Quality Score; yr: year
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Page 9 of 15Table 5 Characteristics of studies investigating plasma levels of cytokines in FMS patients.
Author,
yr.
Diagnosis
criteria
N patients/
controls
a) Material
b) Methods
c) Investigated targets
Results Modified
CEBM
level
NOS W-
MeQS
Wallace,
2001
ACR
56/56 a) serum, PBMC, plasma
b) ELISA
c) IL-1b, IL-2, IL-6, IL-8, IL-10, sIL-2R, IL-1RA,
IFNg, TNF
In FMS compared to controls:
IL-1b, IL-2, IL-6, IL-8, IL-10, sIL-2R, IFNg,
TNF: ↔ in sera +PBMC
IL-1RA: ⇑ in serum
IL-8: ⇑ in plasma
IL-1RA, IL-6: ⇑ in PBMC
IL-6: ⇑ in PBMC of patients with disease
duration > 2 years.
3d 3 0.5
Bazzichi,
2007
ACR
285/40 (16
rheumatoid arthritis
cases, two Sjögren’s
syndrome cases, 16
systemic lupus
erythematosus
cases,
four systemic
sclerosis cases, two
undifferentiated
connective-
tissue disease
cases)/100
a) serum, plasma
b) ELISA
c) IL-1, IL-6, IL-8, IL-10, TNF
No intergroup difference for cytokines. 3d 3 0.2
Bazzichi,
2007
ACR
80/45 a) plasma
b) ELISA
c) IL-1, IL-6, IL-8, IL-10, TNF
IL-10, IL-8, TNF: FMS > controls 3c 3 0.9
Togo,
2008
ACR
7/9 a) plasma
b) Beadlyte multi-cytokine assay
c) IL-10, IL-6, IL-8, IL-1, TNF
No difference between groups. 3d 2 0.8
Zhang,
2008
ACR
92/69 family
members/62
anonymous blood
samples from blood
bank
a) plasma
b) Cytokine Twenty-Five-Plex Antibody
Bead Kit
c) MCP-1, Eotaxin, IP-10, IL-13, IL-5, IL-10,
IL-1b, IL-2, IL-4, IL-6, IL-7, IL-8, IL-12, IL-15,
IL-17, TNF, IFNa, IFNg, GM-CSF, MIG, MIP-
1a, MIP-1b, IL-1RA, IL-2R
Eotaxin and MIP: FMS > controls 3d 3 0.5
Feng,
2009
ACR
100 FMS patients
and family
members/35
unaffected parents
a) plasma
b) Cytokine Twenty-Five-Plex Antibody
Bead Kit
c) Eotaxin, MIP-1a, MCP-1, IP10, IL-12, IL-
1b
Rare missense variants of the MEFV gene
are associated with risk of FMS and are
present in a subset of 15% of FMS
patients. This subset had, on average,
high levels of plasma IL-1b compared to
FMS patients without rare variants,
unaffected family members with or
without rare variants, and unrelated
controls of unknown genotype.
3d 3 0.4
Blanco,
2010
ACR
79/59 a) plasma
b) sandwich enzyme immunoassay kits
c) IL-8, TNF, sTNF-RI, sTNF-RII, MCP-1
Patients with FMS have lower systemic
levels of MCP-2 than controls.
3d 3 0.4
FMS > controls
IL-8: Bazzichi, 2007b; Wallace, 2001
FMS = controls
IL-1b/IL-1: Wallance, 2001; Bazzichi, 2007a and b; Zhang, 2008; Feng, 2009; Togo, 2009
IL-6: Wallance, 2001; Bazzichi, 2007a; Bazzichi, 2007a and b; Zhang, 2008; Togo, 2009
IL-8: Bazzichi, 2007a; Zhang, 2008; Togo, 2009; Blanco, 2010b
TNF: Wallance, 2001; Bazzichi, 2007a; Zhang, 2008; Togo, 2009; Blanco, 2010b
IL-10: Wallace, 2001; Bazzichi, 2007a; Zhang, 2008; Togo, 2009
MCP-1 and IP10: Zhang, 2001;Feng 2009
IL-2: Wallace, 2001; Zhang, 2008
IFNg: Wallace, 2001; Zhang, 2008
Abbreviations:
ACR: American College of Rheumatology; CEMB: Center of Evidence Based Medicine; ELISA: enzyme linked immunosorbent assay; FMS: fibromyalgia syndrome; IL:
interleukin; NOS: Newcastle Ottawa Scale; NR: not reported; PBMC: peripheral blood mononuclear cells; R: receptor; RA: receptor antagonist; W-MeQS: Würzburg
Methodological Quality Score; yr: year
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Page 10 of 15Table 6 Characteristics of studies investigating whole blood levels of cytokines in FMS patients.
Author, yr.
Diagnosis criteria
N patients/controls a) Material
b) Methods
c) Investigated targets
Results Modified CEBM
level
NOS W-MeQS
Üçeyler, 2006
ACR
26/40 a) serum; whole blood
b) qRT-PCR;
ELISA
c) IL-2, IL-4, IL-8, IL-10, TNF, TGF- b1
In FMS compared to controls:
IL-2 ↔
IL-4 ⇓
IL-8 ↔
IL-10 ⇓
TGF-b1 ↔
TNF ↔
3d 4 0.8
Abbreviations:
ACR: American College of Rheumatology; CEMB: Center of Evidence Based Medicine; ELISA: enzyme linked immunosorbent assay; FMS: fibromyalgia syndrome; IL:
interleukin; NOS: Newcastle Ottawa Scale; qRT-PCR: quantitative real-time PCR; W-MeQS: Würzburg Methodological Quality Score; yr: year
Table 7 Characteristics of studies investigating levels of cytokines in PBMC of FMS patients.
Author,
yr.
Diagnosis
criteria
N patients/
controls
a) Material
b) Methods
c) Investigated targets
Results Modified
CEBM
level
NOS W-
MeQS
Hader,
1991
Smythe
12/10 a) CD4+ T-lymphocytes from
PBMC
b) T-cell culture; stimulation
experiments with mitogens
c) IL-2
FMS: higher concentration of mitogen was
necessary to achieve optimal IL-2 secretion; peak
time of IL-2 secretion was delayed.
Addition of calcium did not correct the reduction
in IL-2 secretion in patients with FMS; addition of
phorbole myristate acetate led to normal IL-2
secretion.
3d 2 0.4
Barth,
1999
cite Wolfe,
1985
12 FMS/6
rheumatoid arthritis
or osteoarthritis
controls/6
a) supernatant of PBMC
b) in vitro stimulation of PBMC
with different L-tryptophan,
contaminated L-tryptophan, peak
E;
self established double sandwich
ELISA
c) IL-4, IL-2, INF-g, GM-CSF, IL-5,
IL-10
In vitro stimulation of PBMC with different L-
tryptophan preparations: 6/12 FMS patients, 2/12
controls: IL-5 and IL-10 production
3d 4 0.1
Wallace,
2001
ACR
56/56 a) serum, PBMC
b) ELISA
c) IL-1b, IL-2, IL-6, IL-8, IL-10, sIL-2
R, IL-1 RA, IFNg, TNF
In FMS compared to controls:
IL-1b, IL-2, IL-10, sIL-2 R, IFNg, TNF: ↔ in sera +
PBMC
IL-1 RA, IL-8: ⇑ in sera
IL-1 RA, IL-6: ⇑ in PBMC
IL-6: ⇑ in PBMC of patients with disease duration >
2 years.
3d 3 0.5
Amel
Kashipaz,
2003
ACR
22 FMS/CFS/19 a) PBMC
b) intracellular cytokine stain;
flow cytometry
c) IL-1a, IL-6, IL-10, TNF
In FMS compared to controls:
IL-1a ↔
IL-6 ↔
IL-10 ↔
TNF ↔
3d 2 0.7
Kaufmann,
2007
ACR
22/15 CRPS/37 a) T-cells
b) FACS analysis
c) IL-2, IFN-g, IL-4, IL-10
No difference in percentage of cytokine producing
cells between FMS and controls.
3d 2 0.6
Macedo,
2007
ACR
18/22 a) blood, PBMC
b) automated biochip array;
before and after 1.5 mg of
dexamethasone per os
c) IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-8,
IL-10, IFN-g, TNF
After dexamethasone: reduction of cytokines FMS >
controls.
3d 2 0.4
Ortega,
2010
ACR
9/9 a) PBMC
b) ELISA
c) IL-1b, TNF, IL-6, IL-10
For all cytokines investigated: higher values at
baseline in FMS compared to controls; after aquatic
exercise levels as in controls.
3d 3 0.3
Abbreviations:
ACR: American College of Rheumatology; CEMB: Center of Evidence Based Medicine; ELISA: enzyme linked immunosorbent assay; FMS: fibromyalgia syndrome; IL:
interleukin; NOS: Newcastle Ottawa Scale; PBMC: peripheral blood mononuclear cells; R: receptor; RA: receptor antagonist; s: soluble; W-MeQS: Würzburg
Methodological Quality Score; yr: year
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Page 11 of 15method. A group minimum of three studies was manda-
tory for meta-analysis.
A significant difference between controls and FMS was
found only in two subgroups. When analyzing data of
three studies on the pro-inflammatory cytokine IL-6
plasma levels investigated with ELISA or immunoassay
or bioplex assay, patients with FMS had higher plasma
levels of IL-6 compared to controls (SMD, -0.34; [-0.64,
-0.03] 95% CI; p = 0.03; Table 4). There was also a trend
for elevated serum IL-6 levels in FMS patients compared
to controls (SMD, 1.01; [-0.03, 2.05] 95% [CI]; p = 0.06).
No further intergroup differences were found even when
regarding studies investigating serum, plasma, and whole
blood as one group of “blood” (Table 9).
Patients with FMS have higher plasma levels of IL-6
compared to controls. The discrepancy to the results of
the systematic review (higher plasma IL-8 levels in
patients with FMS) is due to the fact that only few stu-
dies were suitable for meta-analysis.
Discussion
In this systematic review and meta-analysis we set out
to clarify if cytokine profiles in FMS patients differ from
controls analyzing published data available to date.
Applying the modified CEBM levels, NOS, and W-
MeQS we showed that the majority of the studies was
of poor methodological quality. Our systematic review,
in which we also considered study quality (modified
CEBM level; NOS score; W-MeQS) shows that patients
with FMS have higher serum IL-1RA, IL-6, and IL-8
levels compared to controls and that they also have
higher plasma levels of IL-8. Looking at reproduced
results (regardless of the method used and with a mini-
mum of two independent studies) FMS patients do not
differ from controls in serum IL-1b/IL-1, TNF, IL-2, IL-
10, IFN-g, and IL-4 levels; they also do not differ from
controls in plasma IL-1b/IL-1, IL-6, TNF, IL-10, MCP-
1, IP10, IL-2, and IFN-g levels.
Our meta-analysis shows that patients with FMS have
higher plasma levels of IL-6 compared to controls and a
tendency for higher serum levels of IL-6 (p = 0.06). No
further differences could be found.
IL-1RA, IL-6, and IL-8 are pro-inflammatory cytokines
that may have algesic effects. The role of cytokines in
the induction and maintenance of pain is well estab-
l i s h e di na n i m a ls t u d i e sa n da l s oi np a i ns y n d r o m e s[ 5 ] .
Therefore the hypothesis that patients with FMS, who
suffer from generalized pain may have an innate or
acquired imbalance in cytokine production and secretion
is plausible. Higher levels of these cytokines in plasma
and/or serum of patients with FMS may be associated
with pain in FMS. In line with these findings one study
showed lower levels of the anti-inflammatory and
analgesic cytokines IL-4 and IL-10 in FMS patients
compared to healthy controls [30]. However, it remains
elusive, whether these systemic changes in cytokine
levels are the cause of pain in FMS or its consequence.
Longitudinal studies are needed to answer this question.
The main problem in interpreting the results of stu-
dies on cytokines in FMS is that although cytokines
have been investigated in a large number of studies, dif-
ferent methods have been used to analyze different cyto-
kines in diverse material. Therefore a direct comparison
of the results is hardly possible. Results obtained for one
cytokine have mostly not been reproduced, the number
of samples investigated per study was low (7/25 studies
with n < 20 patients), and several studies report conflict-
ing results - even in the same research group [13,14].
Also, possible confounding factors that physiologically
may influence cytokine levels (e.g. circadian production;
depression; physical activity; current infection) were not
controlled in the majority of the studies.
Another problem is that the measurements mostly
were not specifically hypothesis-driven, but were per-
formed following the general assumption that “cytokines
may play a role”. Therefore in the majority of studies a
Table 8 Characteristics of studies investigating levels of cytokines in skin of FMS patients.
Author, yr.
Diagnosis
criteria
N patients/
controls
a) Material
b) Methods
c) Investigated
targets
Results Modified
CEBM
level
NOS W-
MeQS
Salemi, 2003
ACR
53/10 a) skin biopsy
b) RT-PCR, IHC
c) IL-1b, IL-6, TNF
Detectable cytokines in FMS:
IL-1b (19/50)
IL-6 (14/51)
TNF (17/53)
None of the cytokines could be detected in control
skin.
3d 2 0.7
Blanco, 2010
ACR
63/49 a) skin
b) IHC
c) MCP-1, TNF
MCP-1: FMS < controls 3c 3 0.8
Abbreviations:
ACR: American College of Rheumatology; CEMB: Center of Evidence Based Medicine; FMS: fibromyalgia syndrome; IHC: immunohistochemistry; IL: interleukin;
NOS: Newcastle Ottawa Scale; RT-PCR: reverse transcriptions PCR; W-MeQS: Würzburg Methodological Quality Score; yr: year
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Page 12 of 15Table 9 Results of meta-analysis.
Study FMS Controls Weight SMD
Mean Std Total Mean Std Total IV, Random, 95% CI
IL-1: plasma, ELISA or immunoassay
Togo 2009 0.79 0.64 7 1.24 1.17 9 16.4% -0.43 [-1.44, 0.57]
Feng 2009 74.5 116.5 100 45.6 53.1 35 41.3% 0.28 [-0.11, 0.66]
Bazzichi 2007 4.54 9.7 80 7.44 6.62 45 42.3% -0.33 [-0.70, 0.04]
Total (95% CI) 187 89 100.0% -0.10 [-0.58, 0.39]
Heterogeneity: Tau
2 = 0.11; Chi
2 = 5.52, df = 2 (P = 0.06); I
2 = 64%
Test for overall effect: Z = 0.39 (P = 0.69)
IL-6: plasma, ELISA or immunoassay or bioplex assay
Togo 2009 14.0 10.9 7 16.8 15.3 9 9.6% -0.19 [-1.19, 0.80]
Schwarz 2002 1.01 0.47 17 1.45 2.17 17 20.7% -0.27 [-0.95, 0.40]
Bazzichi 2007 2.76 3.99 80 4.34 4.51 45 69.7% -0.38 [-0.74, -0.01]
Total (95% CI) 104 71 100.0% -0.34 [-0.64, -0.03]
Heterogeneity: Tau
2 = 0.00; Chi
2 = 0.15, df = 2 (P = 0.93); I
2 =0 %
Test for overall effect: Z = 2.15 (P = 0.03)
IL-6: serum, ELISA or immunoassay or bioplex assay
Gür 2002 5.52 3.96 81 5.46 1.37 32 25.7% 0.02 [-0.39, 0.43]
Hernandez 2010 16.28 8.13 64 0.92 0.32 25 24.8% 2.20 [1.63, 2.77]
Wallace 2001 7.19 2.02 56 6.3 6.72 36 25.6% 0.20 [-0.22, 0.62]
Wang 2008 2.57 1.38 20 0.92 0.32 25 23.9% 1.71 [1.02, 2.40]
Total (95% CI) 221 118 100.0% 1.01 [-0.03, 2.05]
Heterogeneity: Tau
2 = 1.05; Chi
2 = 51.09, df = 3 (P < 0.00001); I
2 = 94%
Test for overall effect: Z = 1.91 (P = 0.06)
IL-8: plasma, ELISA or immunoassay
Bazzichi 2007 61.89 149.0 80 7.9 17.5 45 41.2% 0.45 [0.08, 0.82]
Blanco 2010 83.0 253.0 79 84.0 253.0 59 42.8% -0.00 [-0.34, 0.33]
Togo 2009 8.4 1.9 7 11.8 5.4 9 16.0% -0.75 [-1.79, 0.28]
Total (95% CI) 166 113 100.0% 0.06 [-0.43, 0.56]
Heterogeneity: Tau
2 = 0.12; Chi
2 = 6.23, df = 2 (P = 0.04); I
2 = 68%
Test for overall effect: Z = 0.25 (P = 0.80)
TNF: serum, ELISA or immunoassay or bioplex assay
Hernandez 2010 20.42 7.24 64 35.73 0.72 25 33.0% -2.46 [-3.05, -1.87]
Wang 2008 3.27 5.08 20 3.89 12.95 80 33.5% -0.05 [-0.54, 0.44]
Üçeyler 2006 7.41 11.01 26 6.7 9.5 40 33.5% 0.07 [-0.42, 0.56]
Total (95% CI) 110 145 100.0% -0.81 [-2.31, 0.70]
Heterogeneity: Tau
2 = 1.70; Chi
2 = 49.74, df = 2 (P < 0.00001); I
2 = 96%
Test for overall effect: Z = 1.05 (P = 0.29)
TNF: plasma, ELISA or immunoassay
Bazzichi 2007 22.59 29.55 80 11.07 6.77 45 28.0% 0.48 [0.11, 0.85]
Blanco 2010 163.0 435.0 79 161.0 319.0 59 28.5% 0.01 [-0.33, 0.34]
Feng 2009 12.2 10.2 100 40.1 73.5 35 27.6% -0.73 [-1.12, -0.33]
Togo 2009 0.24 0.13 7 0.7 0.61 9 16.0% -0.93 [-1.98, 0.13]
Total (95% CI) 266 148 100.0% -0.21 [-0.82, 0.39]
Heterogeneity: Tau
2 = 0.30; Chi
2 = 21.71, df = 3 (P < 0.0001); I
2 = 86%
Test for overall effect: Z = 0.69 (P = 0.49)
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Page 13 of 15large array of cytokines was screened without a clear
hypothesis for each cytokine. This might be one reason
why only few markers were repetitively analyzed, how-
ever, most markers were investigated only once - prob-
ably because they were part of a commercially available
kit. In none of the studies a mechanistical approach was
followed to investigate the mechanisms possibly under-
lying the effect of a specific cytokine in the induction
and maintenance of defined symptoms of FMS. There-
fore also the biological impact of the described changes
in cytokine levels remains elusive. The question is also if
in all studies the most appropriate method was used to
detect the cytokine of interest. The majority of cytokines
have a low expression and it is essential to apply meth-
ods that are sensitive enough. In the last years high- and
ultra-sensitive bioassays have been developed that reli-
ably allow the determination of cytokine proteins in
body fluids. Since in the majority of cytokine studies
analyzed here the sensitivity of the used method was
not given it is not clear if the many negative results
reported are “real” or due to low method sensitivity.
One further point is that there is no validated scoring
system for the quality of laboratory methods in research
papers. Such tools, however, are needed to assess study
results and to compare the results of different studies,
especially when looking at conflicting results. Standardi-
zation of the way laboratory research is performed by
following quality standards and its presentation is war-
ranted. The quality score W-MeQS that we present here
may be one possibility.
In many cases the data provided in the papers were
not applicable for meta-analysis and could not be calcu-
lated from the data presented in the publication. This
fact and the diversity of methods and materials investi-
gated made it almost impossible to form subgroups for
meta-analysis.
Cytokines form a “fragile” system that can be influ-
enced by many factors. The following issues might help
improving the quality and the yield of future cytokine
research in FMS patients: 1) Cytokine secretion follows
circadian rhythmicity; the time points of material asser-
vation should be kept constant. 2) Cytokine secretion
has a large variability; measurements should be per-
formed on two sets of samples and at least two different
methods should be used (e.g. investigation of gene
expression and protein levels). 3) Cytokine levels can be
influenced by many environmental factors and by medi-
cation; patients should therefore be off medication at
the time of material asservation or the possible influence
of medication should be considered when interpreting
the results. 4) Detailed patient characteristics (including
disease duration; pattern of symptoms etc.) are essential
for correlation of the cytokine measurements with clini-
cal data. 5) The formulation of a clear literature-based
hypothesis is warranted at the beginning of the cytokine
study and a power calculation should be performed in
advance. 6) Systemic and local cytokine expression
should be investigated with appropriate methods. To
choose the appropriate method, the expected level of
expression should be taken into account and it should
be made sure that the sensitivity of the method used is
high enough to measure what is to be measured.
Conclusions
The major consequence of our review is that cytokine
research in FMS pathophysiology needs substantial
improvement. More hypothesis-based and mechanistic
studies are needed to understand if distinct cytokines
are involved in causing symptoms of FMS or if they
may be used as biomarkers of FMS symptoms. There is
also a need for defined and applied quality standards for
s t u d yd e s i g na n dp e r f o r m a n c ei nb e n c h - s i d er e s e a r c h
and for standardization rules for study reports and
manuscripts (like STROBE for clinical research). Possi-
ble confounding factors of cytokine levels should be
controlled and a sufficient number of study subjects
should be investigated e.g. following an a priori power
calculation of sample size. Also the performance of pro-
spective studies would be helpful.
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